Healthcare News: Newborn Screening Industry by Market Dynamics 2018 Top Players are Agilent Technologies, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., and ZenTech S.A

Newborn screening tests look for developmental, metabolic, and genetic disorders in infants. It allows steps to be taken before development of symptoms. Although, majority of these illnesses are very rare, they can be treated with early diagnosis. Newborn screening includes over 30 conditions and illnesses. Increasing awareness among parents for disease screening is a major factor driving newborn screening market growth. Furthermore, various government and non-government organizations are actively focused on offering better fetal and maternal care. For instance, in June 2018, the American Society of Hematology (ASH) led a campaign to fight sickle cell disease in Africa and urged governments, particularly in sub-Saharan Africa, to invest in newborn screening of the disease.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/2192

Novel treatments, biomarkers, and technologies are expected to enable various diseases to be considered as potential candidates to be included in New Born Screening (NBS) programs. For instance, new treatments such as Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT), and gene therapy and new pharmacological drugs have allowed autoimmune diseases to be considered as potential candidates to be included in NBS programs.

Market Dynamics

Increasing number of newborn screenings, owing to rising awareness among parents and governments is expected to drive the newborn screening market growth. According to the Centers for Disease Control and Prevention (CDC) 2017, four million infants in the U.S. are routinely screened, using a few drops of blood from their heel, for certain endocrine, genetic, and metabolic disorders. The infants are also tested for hearing loss and Critical Congenital Heart Defects (CCHDs) prior to discharge from a hospital or birth center.
Furthermore, increasing incidence of hospital acquired diseases create an acute need for newborn screening. For instance, according to the Center for Disease Control and Prevention (CDC), in 2011, around one in every 25 infants was infected with at least one hospital acquired infections.

Government initiatives to support screening of newborns is also a major factor driving the newborn screening market. For instance, CDC is working to harness the latest advances in science and technology so that more disorders can be identified accurately and treated quickly. In 2005, CDC established the Newborn Screening Translation Research Initiative (NSTRI) with the CDC Foundation. NSTRI works with corporate, academic, and foundation partners to assure the quality of research methods during both pilot studies and routine screening.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2192

Key players operating in the global newborn screening market include, Agilent Technologies, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., and ZenTech S.A.

Detailed Segmentation:

Global Newborn Screening Market, By Product:
Assay Kits
Hearing Screening Devices
Mass Spectrometer
Pulse Oximetry
Global Newborn Screening Market, By Test:
Blood Test
Cardiac Test
Hearing Test
Urine Test
Global Newborn Screening Market, By Application:
Blood Spot Disease
Critical Congenital Cardiac Disease
Maple Syrup Urine Disease
Hearing Disability
Sickle Cell Disease
Thyroid Disorder

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.